MicroRNA-148a inhibits migration of breast cancer cells by targeting MMP-13

Xue, Jinqi; Chen, Zhiguang; Gu, Xiaoqing; Zhang, Yang; Zhang, Wenhai

doi:10.1007/s13277-015-3926-9

Cited by 34 publications

(29 citation statements)

References 41 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The finding with respect to gender difference is interesting because MMP‐13 was originally detected from breast cancer samples (Freije et al, ). It also seems to be involved in the migration of the breast cancer cells (Xue, Chen, Gu, Zhang, & Zhang, ). Breast cancer is known to principally affect women.…”

Section: Discussionsupporting

confidence: 91%

Salivary MMP‐13 gender differences in periodontitis: A cross‐sectional study from Sweden

Virtanen

Yakob

Tervahartiala

et al. 2017

Clinical & Exp Dental Res

View full text Add to dashboard Cite

We investigated serum and saliva concentrations of matrix metalloproteinases, MMP‐8, MMP‐9, and MMP‐13, and their tissue inhibitor TIMP‐1, in a group of patients with and without periodontitis from Sweden. The hypothesis was that these biomarkers are higher in the periodontitis patients. Ninety patients participated in this cross‐sectional study. Fifty‐one patients had periodontitis whereas 39 were periodontally healthy. Saliva and serum samples were analyzed with immunofluorometric, enzyme‐linked immunosorbent assay and western blot. Results were statistically analyzed with independent t test, Mann–Whitney U test, Bonferroni corrections, and regression analyses. MMP‐13 was not detected in serum, but in saliva, higher values were found among the periodontally healthy compared with periodontitis subjects (0.32 ± 0.26 vs. 0.21 ± 0.23 ng/ml, p < .05). Female gender and clinical attachment loss were the explanatory factors for higher salivary MMP‐13 values with odds ratio 3.08 (95% confidence interval [1.17, 8.11]) and 3.57 (95% confidence interval [1.08, 11.82]), respectively. No statistically significant differences between groups were found in serum and saliva values of MMP‐8, MMP‐9, and TIMP‐1. Contrary to our hypothesis, no statistically significant differences between patients with and without periodontitis were seen in MMP‐8, MMP‐9, and TIMP‐1 values. However, higher MMP‐13 concentrations in saliva were associated with female gender and higher clinical attachment loss. Metabolism of MMP‐13 may thus have some gender implications in periodontitis.

show abstract

Section: Discussionsupporting

confidence: 91%

Salivary MMP‐13 gender differences in periodontitis: A cross‐sectional study from Sweden

Virtanen

Yakob

Tervahartiala

et al. 2017

Clinical & Exp Dental Res

View full text Add to dashboard Cite

show abstract

“…In recent decade, many miRs have been found to have promoting or suppressive effects on breast cancer, such as miR-33b (7), miR-148a (8), miR-181b (9), miR-200b (10), and miR-492 (11). Among these miRs, miR-22 has been reported to act as an oncogene or tumor suppressor (12–14).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1

Zou

Tang

Pan

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

MicroRNAs (miRs), which are a class of small non-coding RNAs, are key regulators of gene expression via induction of translational repression or mRNA degradation. However, the molecular mechanism of miR-22 underlying the malignant progression of breast cancer, remains to be elucidated. The present study aimed to explore the regulatory mechanism of miR-22 in breast cancer cell growth and metastasis. Reverse transcription-quantitative polymerase chain reaction data revealed that miR-22 was significantly downregulated in breast cancer tissues, compared with adjacent non-tumor tissues. Furthermore, the miR-22 levels were further decreased in stage III–IV, compared with stage I–II breast cancer. In addition, low miR-22 levels were significantly associated with the poor differentiation, metastasis and advanced clinical stages of breast cancer. Sirtuin1 (SIRT1) was demonstrated to act as a direct target gene of miR-22 and its protein expression negatively regulated by miR-22 in the MCF-7 breast cancer cell line. Furthermore, SIRT1 expression levels were significantly upregulated in breast cancer tissues, compared with adjacent non-tumor tissues. SIRT1 levels were observed to be increased in stage III–IV when compared with stage I–II breast cancer. miR-22 overexpression decreased the proliferation, migration and invasion of MCF-7 cells, whereas overexpression of SIRT1 eliminated the suppressive effects of the miR-22 overexpression on the malignant phenotype of MCF-7 cells. The results of the present study therefore suggested that miR-22 demonstrated suppressive effects on breast cancer growth and metastasis via targeting SIRT1, and thus the miR-22/SIRT1 axis may be used as a novel and potential therapeutic target for breast cancer in the future.

show abstract

“…It is estimated that there were 234,190 new cases and 40,730 mortalities due to breast cancer in 2015 (1)(2)(3). A number of factors have been verified to contribute to the carcinogenesis of breast cancer, including genetic alterations, epigenetic alterations and environmental factors (4,5).…”

Section: Introductionmentioning

confidence: 99%

Tumor-suppressive microRNA-452 inhibits migration and invasion of breast cancer cells by directly targeting RAB11A

Fan

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Breast cancer is the most common type of malignant tumor in females, and metastasis is the most common cause of breast cancer-associated mortality. Previous studies have identified that abnormal expression of microRNAs is commonly observed in human cancer and may be crucial for cancer metastasis. In the present study, microRNA-452 (miR-452) was investigated for its ability to act as a tumor suppressor in breast cancer. miR-452 expression was quantified in breast cancer tissue samples and cell lines with reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Transwell migration and invasion assays were used to investigate the effect of miR-452 on the migration and invasion capabilities of breast cancer cells. Potential target genes of miR-452 were identified with miRanda and TargetScan. A luciferase reporter assay was performed to validate RAB11A as a putative target of miR-452, and was corroborated by RT-qPCR and western blot analyses. Finally, small interfering RNA (siRNA) was used to knockdown RAB11A expression and confirm whether miR-452 inhibited breast cancer cell migration and invasion via the negative regulation of RAB11A. The results revealed that miR-452 was downregulated in breast cancer tissues and cell lines, and that its downregulation may be associated with breast cancer metastasis, as miR-452 expression inhibited the migration and invasion capacities of breast cancer cells. RT-qPCR and western blot analyses indicated that miR-452 negatively regulated the expression of RAB11A mRNA and protein. The luciferase reporter assay revealed that miR-452 specifically bound to the 3'-untranslated region of RAB11A. Furthermore, inhibition of RAB11A with siRNA inhibited breast cancer cell migration and invasion. In conclusion, the present study has demonstrated that miR-452 may act as a tumor suppressor gene via inhibition of cell migration and invasion by targeting RAB11A in breast cancer.

show abstract

MicroRNA-148a inhibits migration of breast cancer cells by targeting MMP-13

Cited by 34 publications

References 41 publications

Salivary MMP‐13 gender differences in periodontitis: A cross‐sectional study from Sweden

Salivary MMP‐13 gender differences in periodontitis: A cross‐sectional study from Sweden

MicroRNA-22 inhibits cell growth and metastasis in breast cancer via targeting of SIRT1

Tumor-suppressive microRNA-452 inhibits migration and invasion of breast cancer cells by directly targeting RAB11A

Contact Info

Product

Resources

About